Company

Innovent Biologics, Inc.

Headquarters: Suzhou, China

Employees: 5,568

CEO: Dr. De-Chao Yu Ph.D.

HKEX: 1801 -1.95%

Market Cap

HK$63.29 Billion

HKD as of Jan. 1, 2024

US$8.10 Billion

Market Cap History

Innovent Biologics, Inc. market capitalization over time

Evolution of Innovent Biologics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Innovent Biologics, Inc.

Detailed Description

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-303, an adalimumab biosimilar for autoimmune diseases; and IBI-305, a bevacizumab biosimilar to treat metastatic colorectal cancer and non-small cell lung cancer. In addition, it develops IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-308, a human monoclonal antibody for lung, esophageal, and gastric cancer, as well as Hodgkin's lymphoma; and IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further, the company develops IBI-101, an anti-OX40 agonistic antibody for advanced solid tumors; and IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with The University of Texas MD Anderson Cancer Center to co-develop TYVYT, a sintilimab injection; Roche Group for the discovery and development of bispecific antibodies and multiple cell therapies; Ascentage Pharma for joint commercialization of Olverembatinib; NeoCura Bio-Medical Technology Co. Ltd. to study the combination therapy of Sintilimab and neoantigen vaccine NEO_PLIN2101 for cancer treatment; and Eli Lilly and Company, and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Top 1-year algo backtest: +287.69%

$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Innovent Biologics, Inc. has the following listings and related stock indices.


Stock: HKEX: 1801 wb_incandescent

Stock: FSX: 6IB wb_incandescent

Stock: OTC: IVBXF wb_incandescent

Details

Headquarters:

168 Dongping Street

Suzhou Industrial Park

Suzhou, 215123

China

Phone: 86 512 6956 6088

Fax: 86 512 6956 6088